Health & Biotech
ASX Health Stocks: Imugene granted Japan patent, share price is now up 50% in a month
Health & Biotech
InteliCare secures major contract with St John of God Health Care
Health & Biotech
From companion to large animal care – here’s how Apiam’s knowledge of rural vet clinics is driving growth
Health & Biotech
Epsilon clinches first cannabis orders from The Valens, sets eyes on the European markets
Health & Biotech
ASX Health Stocks: Zelira shares jump on $4m cannabis distribution deal to Germany
Health & Biotech
Here’s why this fundie expects MGC Pharma’s stock price to more than double
Health & Biotech
ScoPo’s Powerplays: As focus turns to Delta variant, these ASX health stocks are profiting from COVID-19 testing
Health & Biotech
ASX Health Stocks: Imugene up on PD1-Vaxx cancer study expansion plans
Health & Biotech
In Canada, cannabis is as big as autos… and these ASX stocks are in for the ride
Health & Biotech
MGC Pharma makes inroads in the fight against COVID-19, getting a regulatory nod in Germany and a successful trial in India
Health & Biotech
ASX Health Stocks: M&A winds blow as API gets an upgraded offer from Wesfarmers, jumps 15pc
Health & Biotech
Volpara gets on the fast track as a leading player in lung care with two strategic US partnerships
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.